Does CEL-SCI Corporation (CVM) Represent a Good Investment?

Page 1 of 2

We can judge whether CEL-SCI Corporation (NYSEAMEX:CVM) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There’s no better way to get these firms’ immense resources and analytical capabilities working for us than to follow their lead into their best ideas. While not all of these picks will be winners, research shows that these picks historically outperformed the market when we factor in known risk factors.

Is CEL-SCI Corporation (NYSEAMEX:CVM) a buy here? Prominent investors are taking a pessimistic view. The number of long hedge fund bets stayed the same which is a slightly negative development in our experience. At the end of this article we will also compare CVM to other stocks, including AdCare Health Systems, Inc. (NYSEMKT:ADK), Gulf Coast Ultra Deep Royalty Trust (OTCMKTS:GULTU), and Ballantyne Strong Inc (NYSEAMEX:BTN) to get a better sense of its popularity.

Follow Cel Sci Corp (NYSEMKT:CVM)

In the financial world, there are a lot of gauges investors use to value publicly traded companies. Two of the most underrated gauges are hedge fund and insider trading signals. Our researchers have shown that, historically, those who follow the best picks of the elite hedge fund managers can outpace the S&P 500 by a very impressive amount (see the details here).

Now, we’re going to view the latest action encompassing CEL-SCI Corporation (NYSEAMEX:CVM).

What have hedge funds been doing with CEL-SCI Corporation (NYSEAMEX:CVM)?

Heading into Q4, a total of 4 of the hedge funds tracked by Insider Monkey were long this stock, a change of 0% from the second quarter. With the smart money’s capital changing hands, there exist a few notable hedge fund managers who were increasing their holdings substantially (or already accumulated large positions).

Of the funds tracked by Insider Monkey, Peter S. Park’s Park West Asset Management has the biggest position in CEL-SCI Corporation (NYSEAMEX:CVM), worth close to $0.5 million, comprising less than 0.1%% of its total 13F portfolio. Sitting at the No. 2 spot is Nathan Fischel of DAFNA Capital Management, with a $100,000 position; the fund has 0.1% of its 13F portfolio invested in the stock. Other professional money managers that are bullish include Israel Englander’s Millennium Management, and Bart Baum’s Ionic Capital Management.

Page 1 of 2